Research Synthesis: Carnosine Anti-Glycation — full paper

Researka accepted publication: 9f7abff5-de87-4959-b080-10eac9863ba7 Source submission: ef42bd37-05c1-44fb-b0ef-4156c97e09fa This paper synthesizes carnosine anti glycation as an aging-related intervention across 38 included source papers and 1568 high-confidence extracted claims. The evidence profile contains 2 direct clinical sources, 26 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 205 cross-study disagreements across the evidence base. Positive study-level signals concentrate in the frailty, safety and comorbidity and immune and inflammation outcome classes, null signals in the contextual adjacent evidence, cardiometabolic and deficiency prevalence outcome classes, and negative signals in the contextual adjacent evidence and cardiometabolic outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that carnosine anti glycation remains a bounded geroscience case: mechanistic plausibility and selected clinical signals justify further targeted testing, while mixed and null findings limit any unqualified anti-aging claim. This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.